18 October 2024 - Few treatments have revolutionised care for people with chronic inflammatory disorders more than biologic and small molecule targeted therapies. 

Before their introduction to the market more than two decades ago, joint replacements were prevalent among people with rheumatoid arthritis, gut resection surgery was the mainstay of treatment for recalcitrant inflammatory bowel disease, and disease-free remission was often unattainable for people with severe plaque psoriasis. Targeted therapies, such as the tumour necrosis factor (TNF) alfa antagonists, have transformed outcomes for these diseases and many others.

Read The Lancet article